Biomarker data are not adequate to demonstrate the benefit of a new drug to health technology appraisal agencies appraising drugs for Alzheimer's disease, says BeNeLuxA, a coalition of countries joining forces to improve access to expensive, innovative medicines.
In a short statement, the coalition, which comprises Belgium, the Netherlands, Luxembourg, Austria and Ireland, said it was paying close...








